Streetbeat News

Analyst Ratings

SNOW

A significant bullish stance has been taken on Snowflake (NYSE:SNOW) by a large investor or institution, as evidenced by unusual options activity. The sentiment among these big-money traders is split, with 59% bullish and 40% bearish. The whales have been targeting a price range from $120.0 to $270.0 for Snowflake over the last 3 months. The current price of SNOW is down -2.51% at $172.55. Analysts have mixed views, with downgrades from Wedbush and JMP Securities, and maintained Buy ratings from Needham and Mizuho.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 8:16 pm

PANW

A significant number of investors have taken a bearish stance on Palo Alto Networks (NASDAQ:PANW), with 51% of trades being bearish and 48% bullish. The targeted price range for the company over the last three months has been $195.0 to $306.67. The current price of PANW is up 1.27% at $257.88. Several financial institutions have maintained their positive ratings on Palo Alto Networks, with price targets ranging from $230 to $307.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 8:16 pm

PLUG

Citigroup analyst Vikram Bagri has initiated coverage on Plug Power (NASDAQ:PLUG) with a Buy rating and a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 8:07 pm

WFC

A significant number of investors have taken a bearish stance on Wells Fargo (NYSE:WFC), with 66% of detected trades being bearish. The targeted price range for Wells Fargo over the last 3 months has been $30.0 to $47.5. The current price of WFC is $43.45, up 0.13%. Citigroup, Raymond James, Morgan Stanley, and RBC Capital have all provided their ratings and price targets for Wells Fargo.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 8:02 pm

TMUS

T-Mobile US (NASDAQ:TMUS) has seen unusual options activity, with 20 strange trades detected. Half of the investors opened trades with bullish expectations and half with bearish. The total amount for puts is $469,192 and for calls is $257,615. Whales have been targeting a price range from $55.0 to $140.0 for T-Mobile US over the last 3 months. The current price of TMUS is up 0.03% at $139.37. Wolfe Research upgraded its action to Outperform with a price target of $160, Benchmark downgraded its action to Buy with a price target of $200, and Morgan Stanley maintained their Overweight rating with a price target of $178.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 8:01 pm

GSK

WVE

Raymond James has initiated coverage on WAVE Life Sciences Ltd (WVE) with a price target of $9 and an Outperform rating. The analyst believes that WAVE is leading in RNA editing with WVE-006 for Alpha-1 antitrypsin deficiency (AATD), being developed in collaboration with GSK Plc. The collaboration includes a discovery collaboration that allows GSK to advance up to eight programs and Wave to advance up to three programs. WVE shares are up 7.30% at $3.82.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 7:47 pm

BUD

Anheuser-Busch InBev's (NYSE:BUD) short percent of float has fallen 14.0% since its last report, with 7.37 million shares sold short, which is 0.43% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Anheuser-Busch InBev has less short interest.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:46 pm

BSX

Boston Scientific's (NYSE:BSX) short percent of float has fallen 29.07% since its last report, with 8.72 million shares sold short, which is 0.61% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Boston Scientific has less short interest as a percentage of float, with an average of 3.45%.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:46 pm

BMY

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 3.33% since its last report, with 18.34 million shares sold short, which is 0.87% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. However, it does not necessarily mean that the stock price will rise in the near term. Compared to its peers, Bristol-Myers Squibb has less short interest.

Portfolio Pulse from Benzinga Insights

July 05, 2023 | 7:46 pm

BBIO

BMRN

BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (BMRN) to Outperform from Market Perform, maintaining the price target at $102. The FDA recently approved BioMarin's Roctavian gene therapy for adults with severe hemophilia A. However, the analyst expects Roctavian's uptake to be slower than consensus expectations. The analyst also highlighted the success of Voxzogo's launch in Achondroplasia as a significant growth driver for BioMarin. Meanwhile, recent data from BridgeBio Pharma Inc (BBIO) suggests that Infigratinib can gain significant market share in Achondroplasia.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 7:42 pm